Trials / Completed
CompletedNCT03322618
Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 in Blood Samples
Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 (Monoclonal Antibody IPH4102 Targeting KIR3DL2) in Blood Samples Taken From Patients With Axial Spondyloarthritis and Healthy Volunteers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Assistance Publique Hopitaux De Marseille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
the main objectives are 1. to study the pathophysiological role of KIR3DL2 in axSpA and its relationship with Th17 immunity in HLA-B27 + and HLA-B27- patients and 2. to assess the effect on the pro-inflammatory immune response of a cytotoxic monoclonal antibody IPH4102 (anti-KIR3DL2) in these patients. The study will be carried out on blood samples from 24 patients with axSpA, 12 HLA-B27 + and 12 HLA-B27-, without any drug injection nor direct therapeutic benefit for the participating patients and 12 healthy controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | blood samples | 7 tubes of 6 ml (42 ml of blood ) |
Timeline
- Start date
- 2017-12-18
- Primary completion
- 2019-09-17
- Completion
- 2019-09-17
- First posted
- 2017-10-26
- Last updated
- 2022-09-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03322618. Inclusion in this directory is not an endorsement.